Education
About Us
Working with TipRanks
Follow Us
Talphera, Inc. (TLPH)
:TLPH
Earnings Data
Report Date
Aug 18, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
-0.12Last Year’s EPS
-0.15Same Quarter Last Year
Moderate Buy
Based on 2 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 14, 2025
|% Change Since: 0.00%
|Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment|Positive
The call highlights significant progress in study adjustments and financial management, with strong engagement from new clinical sites. However, challenges with legacy site performance and patient enrollment were notable issues.Company Guidance
During the Talphera First Quarter 2025 Financial Results Conference Call, the company provided key guidance metrics, emphasizing a strategic focus on enhancing the NEPHRO CRRT trial. Notably, the trial size was reduced from 166 to 70 patients, and the company activated additional high-volume sites, which include 3 new sites with 5 more expected by mid-year, to expedite patient enrollment. Talphera also completed a PIPE financing, structured in three tranches, with a total commitment of $14.8 million contingent on enrollment milestones. Financially, the company reduced its cash operating expense guidance to a range of $17 million to $19 million for 2025, down from prior estimates, and reported a first-quarter cash balance of $5.4 million. These changes, alongside the potential compassionate use IDE discussions, are intended to support the completion of the study by year-end, with an FDA approval for Niyad anticipated in 2026.FDA Approval for NEPHRO CRRT Trial Adjustments
The trial received FDA approval for a significantly decreased study size from 166 to 70 patients, removal of certain exclusion criteria, and activation of additional high-volume sites to accelerate enrollment.
Successful PIPE Financing
Completed a PIPE financing structured in three equal tranches of $4.925 million, with conditions that are expected to be achieved within the year.
Cost Reduction and Financial Management
Reduced cash operating expenses from $4.2 million in Q1 2024 to $2.9 million in Q1 2025, with further reductions in personnel expenses and other administrative costs.
High Engagement with New Clinical Sites
Added 3 new sites with 5 more expected by mid-year, all fitting the new target profile, enhancing engagement and efficiency in contracting.
TLPH Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
TLPH Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 14, 2025 | $0.51 | $0.49 | -3.92% |
Mar 31, 2025 | $0.50 | $0.53 | +6.00% |
Nov 13, 2024 | $0.89 | $0.66 | -25.84% |
Aug 14, 2024 | $0.86 | $0.87 | +1.16% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Talphera, Inc. (TLPH) report earnings?
Talphera, Inc. (TLPH) is schdueled to report earning on Aug 18, 2025, TBA Not Confirmed.
What is Talphera, Inc. (TLPH) earnings time?
Talphera, Inc. (TLPH) earnings time is at Aug 18, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is TLPH EPS forecast?
TLPH EPS forecast for the fiscal quarter 2025 (Q2) is -0.12.